A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry

References

• Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
   Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, et al. German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai B, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–2380.
   PubMed Web of Science ®Google Scholar
• Advani RH, Chen H, Habermann TM, et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic in. Br J Haematol 2010;151:143–151.
   PubMed Web of Science ®Google Scholar
• Hasselblom S, Ridell B, Nilsson-Ehle H, et al. The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma – a population-based study. Leuk Lymphoma 2007;48:736–745.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's disease. N Engl J Med 1998;339:1506–1514.
   Google Scholar
• Federico M, Vitolo U, Zinzani PL et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000;95:783–789.
   Google Scholar
• Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol 1989;72:141–149.
   PubMed Web of Science ®Google Scholar
• Osby E, Askling J, Landgren O, et al. Parental longevity and prognosis in elderly patients with aggressive non-Hodgkin's lymphoma. Acta Oncol 2004;43:297–301.
   PubMed Web of Science ®Google Scholar
• Riihijarvi S, Taskinen M, Jerkeman M, et al. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 2011;86:124–128.
   PubMed Web of Science ®Google Scholar
• Carella AM, de Souza C, Luminari S, et al. The prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Limfoni/Grupo de Estudos em Molėstias Onco-Hematológicas retrospective study. Leuk Lymphoma. 2013;54:53–57.
   PubMed Web of Science ®Google Scholar
• Müller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012;119:3276–3284.
   PubMed Web of Science ®Google Scholar
• Siddiqui M, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 2006;134:596–601.
   PubMed Web of Science ®Google Scholar
• Talauikar D, Choudhury A, Shadbolt B, et al. Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas. Leuk Lymphoma 2008;49:959–964.
   PubMed Web of Science ®Google Scholar
• Feng J, Wang Z, Guo X, et al. Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis. Int J Hematol 2012;95:143–148.
   PubMed Web of Science ®Google Scholar
• Gaudio F, Giordano A, Perrone T, et al. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab. Acta Haematol 2011;126:44–51.
   PubMed Web of Science ®Google Scholar
• Fukuhara S, Watanabe T, Munakata W, et al. Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution. Eur J Haematol 2011;87:434–440.
   PubMed Web of Science ®Google Scholar
• The international Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Swan F, Velasquez WS, Tucker S, et al. A new serologic staging system for large-cell lymphoma based on initial β2-macroglobulin and lactate dehydrogenase levels. J Clin Oncol 1989;7:1518–1527.
   PubMed Web of Science ®Google Scholar
• Chihara D, Oki Y, Ine S, et al. Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan. Eur J Haematol 2010;84:493–498.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kinoshita T, Itoh K, et al. Pretreatment total serum protein is a significant prognostic factor for outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma 2010;51:813–821.
   PubMed Web of Science ®Google Scholar
• Ngo L, Hee SW, Lim LC, et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 2008;49:462–469.
   PubMed Web of Science ®Google Scholar
• Dansk Lymfom Gruppe Årsrapport 2011. Available from: www.lymphoma.dk
   Google Scholar
• Harrel FE Jr, Lee KL, Mark DB. Tutorial in biostatistics: multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing error. Stat Med 996;15:361–387.
   Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004;23:2109–2123.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837–842.
   PubMed Web of Science ®Google Scholar
• Held G, Zeynalova S, Murawski N, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-Cell lymphoma and skeletal involvement. J Clin Oncol 2013;31:4115–4122.
   PubMed Web of Science ®Google Scholar
• Székely E, Hagberg O, Arnljots K, et al. Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study. Leuk Lymphoma 2014;55:1838–1843.
   PubMed Web of Science ®Google Scholar
• Dalia S, Chavez J, Little B, et al. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol 2014;93:1305–1312.
   PubMed Web of Science ®Google Scholar
• Oki Y, Yamamoto K, Kato H, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients survival benefit from rituximab. Eur J Haematol 2008;81:448–453.
   PubMed Web of Science ®Google Scholar
• Kim DH, Baek JH, Chae YS, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007;21:2227–2230.
   PubMed Web of Science ®Google Scholar
• Cox MC, Nofroni I, Laverde G, et al. Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 2008;141:265–268.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow K, Habermann TM, et al. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol 2009;84:93–97.
   PubMed Web of Science ®Google Scholar
• Song MK, Chung JS, Seol YM, et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol 2010;21: 140–144.
   PubMed Web of Science ®Google Scholar